Chief medical Fool Brian Orelli thinks that newly approved multiple sclerosis drug Gilenya from Novartismight not grab much of the MS therapy market after all. But Teva Pharmaceutical , which makes established MS drug Copaxone, seems to be shaking in its boots.
For generic-drug companies, margins are ultimately everything. The business is built on volume and how efficiently a company can produce copycat drugs.
Welcome to "11 O'Clock Stock." Here at Fool.com, we'll be finding a new great stock at 11 a.m. ET every weekday for 50 days. Better yet, we're so confident in the picks that we're investing $50,000 of the Fool's own money in them! To hear more about the series, click here to see a video from Motley Fool co-founder Tom Gardner. Can't make it at 11 a.m. ET? Come back to Fool.com, and we'll have the article in our Top Stories section 24 hours a day.